Meeder Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Meeder Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,824	Closed	-$68K	–	1889
2018 Q3	$68K	Buy	+3,824	New	+$65.7K	0.01%	717
2018 Q1	–	Sell	-235	Closed	-$1K	–	1838
2017 Q4	$1K	Sell	235 -2,075	-90%	-$9.89K	﹤0.01%	1628
2017 Q3	$3K	Buy	2,310 +1,461	+172%	+$2.04K	﹤0.01%	1425
2017 Q2	$1K	Sell	849 -885	-51%	-$1.9K	﹤0.01%	1594
2017 Q1	$4K	Sell	1,734 -3,923	-69%	-$9.08K	﹤0.01%	1221
2016 Q4	$14K	Buy	+5,657	New	+$16.2K	﹤0.01%	704

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Meeder Asset Management's ECYT Position: Q4 2018 in Review

Meeder Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 3,824 shares — an estimated $68K sold.

Meeder Asset Management first reported a position in ECYT in Q4 2016 and held it in 6 quarters. The position peaked at $68K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Meeder Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Meeder Asset Management sold 3,824 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $68K.
Meeder Asset Management first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Meeder Asset Management's Endocyte, Inc. Common Stock position peaked at $68K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.